HepQuant

Very pleased to announce that medical diagnostics industry veteran Kelly R. Pitts, Ph.D., is our new Chief Operating Officer! https://hepquant.com/press-releases/kelly-pitts-appointed-chief-operating-officer/

New Year, New Digs! https://hepquant.com/press-releases/hepquant-lab-moves-to-new-location/

Always enjoy seeing old friends and meeting new ones at the Rocky Mountain Life Science Investor and Partnering Conference, held again this year in Vail and hosted by the Colorado BioScience Association. (Photo courtesy of the Colorado BioScience Association)
, ,

An important milestone: Our HepQuant laboratory has achieved COLA accreditation for laboratory quality assurance.

Awarded COLA Accreditation - US Clinical Laboratory Improvement Act NEWS RELEASE HepQuant Awarded COLA Accreditation for Meeting US Clinical Laboratory Improvement Act (CLIA) and Other Regulatory Requirements DENVER (Aug. 24, 2022) -- HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in pat...

On international women’s day - a shout out to some superb women leading the way at HepQuant! We also want to encourage women of all ages to pursue their passions in the field of science and medicine.

Our recent publication in Alimentary Pharmacology & Therapeutics examines the SHUNT test results in relation to the risk of liver decompensation in cirrhotic patients when their disease severity index (DSI) is ≥ 24 or greater. Read more: http://bit.ly/3pOTBb3

Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test - PubMed The SHUNT test is a novel, noninvasive test that predicts risk of decompensation in previously compensated patients. DSI ≥24 is independently associated with risk for clinical decompensation, liver transplantation, death and hospitalisation.